Full-year 2025 guidance: non-GAAP operating margin -- Expected between 23.5% and 24.5%, reflecting increases in sales and ...

One clinical-stage biotech is defying gravity—here’s why its record-breaking run is catching institutional attention.

Net Income -- $7.6 million, down from $9.3 million. Net income attributable to Karat ( KRT +1.51%) was $7.3 million, or $0.36 ...

Q4 2025 guidance -- Projected total revenue of $371 million to $377 million; subscription revenue of $258 million to $261 ...

Relacorilant NDA updates -- FDA PDUFA date set for Dec. 30, 2025 (hypercortisolism); platinum-resistant ovarian cancer PDUFA ...

Acquisition Announcement -- VSE Corporation ( VSEC 0.75%) signed a definitive agreement to acquire Aero 3 for $350 million in ...

Upcoming product launches -- AMP-007 inhalation on track for mid-2026 launch targeting a $1.5 billion market; generic ...

Total production -- Reached a quarterly record of approximately 1.62 million BOEs per day, reflecting a 19% increase, or ...

Both of these electric air taxi pioneers have sold off hard recently, creating a potential entry point for patient investors.

PN-943 (IBD Program) -- Oral, gut-restricted alpha-4-beta-7 integrin antagonist demonstrated greater than threefold improved ...

Disposition Activity -- Q3 proceeds totaled $19.3 million, with $4.6 million in gains; year-to-date sales reached $133.8 ...

BradyScan App Launch -- Announced as available on Android and Apple, supporting barcode generation, scanning, security ...